Pandorum Technologies Raises USD 18 Mn in Series B Funding Led by Protons Corporate The round also saw participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Biotechnology startup Pandorum Technologies has raised USD 18 million in a Series B funding round led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others.
Advisor and investor Bandana Kankani guided the transaction, focusing on aligning the investment structure with the company's long-term value creation goals.
The fresh capital will be used to advance Pandorum's clinical-stage programs, scale up manufacturing operations, and expand market access across the United States, Japan, and the Middle East. Part of the funding will also be allocated to strengthening regulatory capabilities and clinical development infrastructure as the company prepares for broader global trials.
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates in the regenerative medicine and biotechnology space, developing programmable, exosome-based tissue regenerative therapies.
The company has operational presence in both India and the United States, reflecting its focus on global clinical translation and manufacturing.
Pandorum follows a globally distributed manufacturing strategy. It has partnered with AGC Biologics to support manufacturing for the US and European markets, while Nucelion Therapeutics, a subsidiary of Bharat Biotech, provides supply support across the Asia-Pacific region. The company is also exploring additional partnerships in the Middle East to strengthen regional access and distribution.
According to startup data platform TheKredible, Pandorum has raised approximately USD 43 million to date, including an USD 11 million extension of its Series A funding secured last year.
The company's primary clinical focus is on ocular surface diseases, including Stevens–Johnson Syndrome and Neurotrophic Keratitis. Its lead ophthalmology program, Kuragenx, has received Orphan Drug Designation from the US Food and Drug Administration.
Beyond ophthalmology, Pandorum is expanding its technology platform to address inflammatory and degenerative conditions affecting organs such as the lung, liver, and nervous system.
Pandorum's clinical translation efforts are supported by a network of internationally recognised clinicians, including Dr. Virender Singh Sangwan of Dr. Shroff's Charity Eye Hospital in New Delhi, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine in Chicago.
